We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.05 | 2.52% | 42.485 | 42.84 | 42.31 | 42.70 | 1,435,485 | 16:19:15 |
From May 2019 to May 2024
LONDON--GlaxoSmithKline PLC (GSK.LN) said Thursday that the U.S. Food and Drug Administration has approved Flonase Allergy Relief as an over-the-counter treatment for temporary relief of the symptoms of hay fever or upper respiratory allergies.
The U.K. drug maker said Flonase Allergy Relief will be available over the counter in early 2015.
GlaxoSmithKline shares closed Thursday at GBP14.70, valuing the company at GBP71.25 billion.
Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
